SALT LAKE CITY , Oct. 21, 2024 /PRNewswire/ — Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the “Company” or “Co-Dx”), with its unique patented platform, Co-Diagnostics, a molecular diagnostics company aimed at developing molecular diagnostic tests, today announced that it will have a booth at African Health/Medlab Africa in Cape Town, South Africa from October 22 to 24, 2024.
According to the conference website, the conference is the largest gathering of healthcare companies, technologies, products and services in the sub-Saharan region and includes regional sales representatives, government representatives, research executives, purchasing/ It is described as catering to an audience of procurement managers. We have people from all over the world attending meetings with world-class suppliers and manufacturers.
Co-Dx believes that this exhibition will contribute valuable insights into a market that is expected to play an important role in the company’s future. In a report published in September 2023, WHO estimated that 2.5 million people contracted tuberculosis (TB) in the African region in 2021, while the difference between probable and confirmed TB cases was It was pointed out that there remained a large difference. Co-Dx has several infectious disease tests in various stages of development for its upcoming Co-Dx™ PCR home and point-of-care platform*, including testing for tuberculosis.
Additionally, in an update on the Logix Smart® Mpox (2-Gene) RUO test last month, the company stated that in silico analysis shows that the test should retain full reactivity against known mpox strains. reported that it was shown. This comes after the Africa CDC and WHO announced in August that mpx (formerly monkeypox) was classified as a Public Health Emergency of Continental Security (PHECS) and a Public Health Emergency of International Concern (PHEIC), respectively. This is a continuation of what was announced.
Click here for more information about the conference. To learn more about our diagnostic products, please visit us at booth H1/B1.
*The Co-Dx PCR platform (including Co-Dx PCR Home™, Co-Dx PCR Pro™, mobile app, and all associated tests and software) is subject to review by the FDA and/or other regulatory agencies. Yes, it is available for sale. The Co-Dx PCR Pro instrument and Co-Dx COVID-19 test are currently under review by the FDA.
About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures, and markets cutting-edge diagnostic technologies. Our technology is utilized for tests designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The company also uses its proprietary technology to design specific tests for Co-Dx PCR home and point-of-care platforms to identify genetic markers for use in non-infectious disease applications. Forward-looking statements:
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA) and is subject to a number of risks and uncertainties. Forward-looking statements include words such as “believe,” “expect,” “estimate,” “intend,” “may,” “plan,” “will” and similar expressions; They can be identified by the negative forms of these words. Such forward-looking statements are based on facts and circumstances existing at the time such statements are made and expectations regarding future facts and circumstances. Forward-looking statements in this release include statements regarding our readiness to introduce a new PCR diagnostic platform designed for home and point-of-care use and the potential for the African market to play an important role in our future; Contains the description. Actual results may differ materially from those intended or anticipated by such forward-looking statements. Readers of this press release are cautioned not to place undue reliance on forward-looking statements. Due to certain risks and uncertainties, there can be no assurance that anticipated results will occur in a timely manner. A discussion of this can be found in the Risk Factor Disclosure section of our filed Annual Report on Form 10-K. The Company filed with the Securities and Exchange Commission (SEC) on March 14, 2024 and is included in other filings with the SEC. The Company undertakes no obligation to update any forward-looking statements relating to the matters discussed in this press release, except as required by applicable securities laws.
View original content to download multimedia: https://www.prnewswire.com/news-releases/co-diagnostics-inc-to-host-booth-at-medlab-africa-in- cape-town-on-oct-22 -24-2024-302281585.html
Source Joint Diagnosis
